Lumov Health has secured a ₹10 crore seed round led by Incubate Fund Asia, marking a major step forward in building India’s next-generation musculoskeletal (MSK) care products platform. The round brings in institutional investors such as QRG Investments, IIMA Ventures, SIDBI, and GIRLS II WOMEN GODS LEADING ANGELS signalling rising investor conviction in India’s rapidly expanding orthopaedic recovery and rehabilitation market.With MSK disorders becoming one of India’s fastest-growing health burdens, the funding comes at a pivotal time. Lumov plans to scale its orthopaedic recovery portfolio, expand operations across Delhi NCR, Hyderabad, and Mumbai, and strengthen manufacturing capacity to meet surging national demand for clinically backed recovery and pain-management solutions.
Why This Matters
India is experiencing an unprecedented MSK health surge driven by sedentary lifestyles, rising sports injuries, ageing populations, and post-surgical recovery needs.While diagnostics and care delivery have accelerated, the physical product layer remains heavily fragmented.
Lumov is positioning itself to fill this gap through:
- high-quality orthotics and rehabilitation aids,
- surgeon-led product development,
- premium, clinically validated recovery solutions, and
- integrated product design tailored to India’s pain-care realities.
This blend of clinical expertise and product innovation is what investors see as the foundation of a category-defining MSK brand.
Leadership Perspectives
Saumaric Dangwal & Ankit Gupta, Co-founders, Lumov Health:
“India is in the middle of an orthopaedic health crisis. We are building the premium product layer — orthotics, rehab aids, pain-management solutions — designed to accelerate recovery and help people live pain-free, active lives.”
Rajeev Ranka, Partner, Incubate Fund Asia:
“The MSK care category is poised for significant innovation. Lumov’s surgeon-led approach and deep market understanding give us high confidence that they can build a category-defining company.”
Ramesh Sharma, President, QRG Investments:
“Lumov impressed us with its vision to build an integrated MSK products platform. Their clinical partnerships, clarity of thought, and execution speed position them strongly to lead India’s musculoskeletal care market.”
Strategic Implications
With this funding, Lumov Health is set to:
- Expand across three major metros,
- Accelerate manufacturing for scale,
- Broaden its orthopaedic recovery product line,
- Build a clinically integrated MSK innovation platform, and
- Establish early leadership in an underserved, high-growth health category.
The company is crafting the infrastructure for what could become India’s most comprehensive MSK products ecosystem.
Lumov Health’s seed round isn’t just a capital raise it’s a vote of confidence in a clinically driven, design-first approach to musculoskeletal recovery. As India’s MSK crisis intensifies, Lumov is emerging as a pivotal force shaping accessible, high-quality, research-backed recovery solutions for millions.A new category creator in the making built at the intersection of clinical precision, design innovation, and large-scale health demand.
 care products platform.){kind=link}